PCSK9 Inhibition: Does Lipoprotein Size Matter?

Karim Si-Tayeb; Bertrand Cariou

doi:10.1161/JAHA.115.002806

PCSK9 Inhibition: Does Lipoprotein Size Matter?

J Am Heart Assoc. 2015 Nov 19;4(11):e002806. doi: 10.1161/JAHA.115.002806.

Authors

Karim Si-Tayeb¹, Bertrand Cariou²

Affiliations

¹ INSERM, UMR1087, l'institut du thorax, Nantes, France (K.S.T., B.C.) CNRS, UMR 6291, Nantes, France (K.S.T., B.C.) Université de Nantes, Nantes, France (K.S.T., B.C.).
² INSERM, UMR1087, l'institut du thorax, Nantes, France (K.S.T., B.C.) CNRS, UMR 6291, Nantes, France (K.S.T., B.C.) Université de Nantes, Nantes, France (K.S.T., B.C.) CHU Nantes, l'institut du thorax, CIC Endocrinology-Nutrition, Nantes, France (B.C.).

No abstract available

Keywords: Editorials; PCSK9; diabetes mellitus; lipids and lipoproteins; low‐density lipoprotein‐cholesterol; low‐density lipoprotein‐particles; metabolic syndrome; monoclonal antibodies.

Publication types

Editorial
Comment

MeSH terms

Cholesterol, LDL
Humans
Lipoproteins*
Proprotein Convertases*
Serine Endopeptidases

Substances

Cholesterol, LDL
Lipoproteins
Proprotein Convertases
Serine Endopeptidases